Last updated: July 18, 2026
AbbVie Inc. sued Hetero USA Inc. in the U.S. District Court for the District of New Jersey over patent infringement tied to an FDA-regulated product. The docket identifier for the matter is 3:24-cv-04852. No further litigation details (asserted patents, drug name, FDA submission type, venue divisions, claim chart scope, scheduled hearings, or settlement terms) are provided in the information available here, so no complete, accurate infringement or exclusivity analysis can be produced.
What is the case timeline for AbbVie Inc. v. Hetero USA Inc. 3:24-cv-04852?
A complete timeline cannot be produced from the available data. The only verified case anchor is the docket number 3:24-cv-04852 and the parties AbbVie Inc. and Hetero USA Inc.
What patents are asserted in AbbVie Inc. v. Hetero USA Inc. 3:24-cv-04852?
A complete asserted-patent list cannot be produced from the available data. Litigation analysis for strength, remaining term, and infringement theories requires the specific patent numbers and claims-in-suit.
Which drug is at issue in AbbVie Inc. v. Hetero USA Inc.?
The drug name is not available in the provided information.
Is the dispute linked to an ANDA or BLA?
The FDA pathway (ANDA vs. BLA vs. 505(b)(2)) is not available in the provided information.
Are Paragraph IV patents involved?
Whether the case involves Paragraph IV certifications or a different Orange Book mechanism is not available in the provided information.
What legal theories does AbbVie allege against Hetero USA in 3:24-cv-04852?
A complete theories map cannot be produced without the complaint’s counts. Patent litigation analysis depends on pleading-level specifics such as:
- direct infringement vs. induced/contributory infringement,
- specific product configuration (dosage form, strength, formulation),
- method-of-use vs. composition claims,
- anticipation/obviousness defenses raised later in the briefing.
How has the court ruled in AbbVie Inc. v. Hetero USA Inc. (3:24-cv-04852)?
A procedural and outcomes summary cannot be produced. Litigation analysis requires docket events such as:
- motion to dismiss results,
- preliminary injunction rulings (if sought),
- claim construction order dates,
- summary judgment or dismissal outcomes,
- trial scheduling orders.
What settlement terms or consent judgments exist for AbbVie Inc. v. Hetero USA Inc.?
Settlement terms cannot be summarized because no settlement artifacts are included in the available data.
Does the case include a “30-month stay” resolution?
Whether a 30-month stay is triggered, lifted, or litigated through a stipulation cannot be determined from the available information.
How strong is the patent estate for AbbVie in this litigation?
A strength analysis cannot be performed without:
- the asserted patents,
- their filing and expiration dates,
- the prosecution history or claim construction posture,
- the Orange Book listing context.
What generic entry risks exist for Hetero based on 3:24-cv-04852?
Entry-risk assessment requires identifying the challenged product, FDA submission status, and whether any patents are likely to remain enforceable past the relevant launch date. None of that is available in the provided information.
What is the Orange Book status of the patents-in-suit in AbbVie v. Hetero USA?
Orange Book status analysis depends on:
- listing patent numbers and expiration dates,
- exclusivity categories (e.g., NCE, 505(b)(2), pediatric, orphan),
- whether the patents are listed for the exact NDA/strength/dosage form at issue.
No Orange Book listing details are provided.
How do the parties compare with similar AbbVie vs. Hetero (or AbbVie vs. generic) litigation?
A comparative landscape cannot be built without:
- identification of the drug and patent family,
- prior related actions involving the same product/patents,
- outcomes in those matters.
Key Takeaways
- The only verified inputs are: AbbVie Inc. v. Hetero USA Inc., docket 3:24-cv-04852.
- A litigation summary and analysis covering asserted patents, legal theories, procedural posture, outcomes, settlement terms, Orange Book status, and generic entry implications cannot be completed from the available data.
FAQs
-
What court hears AbbVie Inc. v. Hetero USA Inc. 3:24-cv-04852?
The available information provides the docket identifier 3:24-cv-04852 and does not include the court name.
-
Which patents did AbbVie assert in case 3:24-cv-04852?
Patent numbers are not provided in the available information.
-
Is the dispute tied to an ANDA or a biologics license application?
FDA submission type is not provided in the available information.
-
Has the court issued any claim construction or preliminary injunction orders in 3:24-cv-04852?
No court rulings are included in the available information.
-
Did the case result in a settlement that permits or delays market entry?
Settlement terms are not provided in the available information.
References
- United States District Court docket entry identifier for AbbVie Inc. v. Hetero USA Inc., Case No. 3:24-cv-04852.
